Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Report - Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2017" report to their offering.

This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects.

The Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 7, 4, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview
  3. Therapeutics Development
  4. Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
  5. Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis
  6. Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies
  7. Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes
  8. Reflux Esophagitis (Gastroesophageal Reflux Disease) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies
  13. Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes
  14. Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
  • Ahn-Gook Pharmaceutical Co Ltd
  • Alveonix AG
  • Cempra Inc
  • Daewoong Pharmaceutical Co Ltd
  • Eisai Co Ltd
  • Ilyang Pharmaceutical Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Takeda Pharmaceutical Company Ltd
  • Vecta Ltd
  • Wockhardt Ltd
  • Yuyu Pharma Inc

For more information about this report visit http://www.researchandmarkets.com/research/cclw2d/reflux

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs